A new study uses real-time fMRI neurofeedback to help depression patients reduce rumination by training specific brain circuits in a gamified environment.

A multiscale map of the brain's histamine system reveals its role in ADHD and depression, offering new targets for ...

The treatment consists of a Bluetooth headset that patients can connect to an app on their smartphones. It could mark a ...

Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation ...

Young women with depression are more likely to have lower levels of taurine in their hippocampus than healthy controls. The corresponding study was published in Biological Psychiatry. Between 2013 and ...

ALTO-207 is a fixed-dose combination of pramipexole, a dopamine D3/D2 agonist with antidepressant activity demonstrated across multiple prior studies, and ondansetron, a 5-HT3 antagonist anti-emetic.

On Tuesday, Alto Neuroscience, Inc. (NASDAQ:ANRO) announced an asset purchase agreement with Chase Therapeutics Corporation for a portfolio of dopamine agonist drug combinations for ...

A study of 1,800 UK participants revealed that poorer cognitive performance did not predict depression relapse in previously ...

A new study found that depression may increase the risk of menstrual pain through factors like sleep disturbances. The findings suggest that treating sleep and mental health issues may help relieve ...

Reunion Neuroscience, Inc., a clinical-stage biopharmaceutical company committed to revolutionizing the treatment of underserved mental health disorders through the advancement of next-generation ...